Tampa, FLNCT06947083Now EnrollingIRB Ready

Myeloma Clinical Trial in Tampa, FL

Access cutting-edge myeloma treatment through this clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute

Quick Self-Assessment

See if you qualify for this Tampa location

Preparing your pre-screening questions…

Expert Care in Tampa

Access myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myeloma treatment provided free

Apply for This Tampa Location

Check if you qualify for this myeloma clinical trial in Tampa, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tampa

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tampa site if eligible
  4. 4Begin participation

About This Myeloma Study in Tampa

The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Who Can Participate

Inclusion Criteria

Understand and voluntarily sign an informed consent form.
Have received commercial cilta-cel within 3-6 months for relapsed refractory myeloma and have high risk cytogenetics by IMW (del17p, or t(4;14) or t(14;16) or history of EMD, and must not have evidence of progressive disease by IMWG criteria(Appendix B) following CAR-T cell therapy.
Have received \>2 prior treatment regimens including an immunomodulatory drug, a proteasome inhibitor and a CD38 monoclonal antibody.
Able to adhere to the study visit schedule and other protocol requirements.
Patients must have available clonoseq ID prior to enrollment to track MRD status.
Eastern Cooperative Group (ECOG) Performance Status of 0 or 1.
Serum bilirubin levels ≤1.5 times the upper limit of the normal range for the laboratory (ULN), unless related to Gilbert syndrome.
Serum AST or serum ALT levels ≤2 x ULN.
Must have adequate bone marrow function.

Exclusion Criteria

Ongoing active infection defined as an infection that is worsening despite therapy and causing symptoms or requiring intravenous antibiotic treatment.
Ongoing CRS or ICANS of any grade.
Active plasma cell leukemia.
Patients with CNS involvement, including meningeal involvement.
Patients with history of Guillain-Barre syndrome.
Uncontrolled medical problems such as diabetes mellitus, congestive heart failure, coronary artery disease, hypertension, unstable angina, arrhythmias), pulmonary, hepatic and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma, which in the opinion of the treating physician pose an unacceptable risk to the patient.
Pregnant or lactating females.
Concurrent use of other anti-cancer agents or treatments.
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible. Note: patients with hepatitis C previously treated with curative intent are considered eligible.
Patients with renal failure requiring dialysis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT06947083) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myeloma Treatment Options in Tampa, FL

If you're searching for myeloma treatment options in Tampa, FL, this clinical trial (NCT06947083) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Tampa, FL

See all multiple myeloma clinical trials recruiting in Tampa — not just this study.

Browse Multiple Myeloma Trials in Tampa →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Tampa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tampa, FL